SAA2 and metabolic dysfunction-associated steatohepatitis: To evaluate the role of SAA in metabolic dysfunction-associated steatohepatitis (MASH) resolution, we compared serum samples from WD (30 weeks) and WDA (20 weeks) followed by 4 weeks resolution, from a previously reported experiment.20